Updated:
Chimerix
Chimerix, now part of Jazz Pharmaceuticals, is a biopharmaceutical firm focused on rare disease and HER2-targeted cancer therapies.
Chimerix
Jazz Pharmaceuticals is focused on improving patients’ lives by identifying, developing, and commercializing products that address unmet medical needs.
General information
Firm type
other
Year founded
—
AUM
Undisclosed
Location
Region
North America
Country
United States
City
Durham
Corporate office
Durham, NC, United States
Sector focus
Frequently asked questions
Is Chimerix still an independent company?
No, Chimerix was acquired by Jazz Pharmaceuticals in 2024 and is now integrated into Jazz's rare disease and oncology business.
What therapeutic areas does Chimerix focus on?
Chimerix focuses on rare diseases and oncology, particularly HER2-expressing cancers and central nervous system tumors.
Does Chimerix have any approved drugs?
Chimerix's pipeline includes clinical-stage candidates; it has not disclosed any approved products, as its programs are now part of Jazz Pharmaceuticals' development portfolio.
Where is Chimerix located?
Chimerix is headquartered in Durham, North Carolina, United States.
How does Chimerix differ from Jazz Pharmaceuticals?
Chimerix was an independent biotech before its acquisition by Jazz. It now operates as a research and development arm within Jazz, contributing its rare disease and oncology pipeline.
Profile maintained by Altss using OSINT (open-source intelligence), regulatory filings, licensed data partners, and verified direct submissions. Read the methodology. Last updated: . Continuous refresh with full update cycles at least every 30 days.
Need institutional-grade insight on investors?
Altss delivers:
Prefer a guided tour?
We’ll walk you through: